Danaher’s share decline looks like a buying opportunity after a solid quarter

In this photo illustration, the Danaher Corporation logo seen on a smartphone with the Danaher Corporation stock information in the background.

Igor Golovnev | Light Rocket | Getty Images

Life sciences and medical diagnostics company Danaher (DHR) reported better than expected earnings and sales for the fourth quarter. We see the price decline as unjustified and as an opportunity.

Leave a Reply

Your email address will not be published. Required fields are marked *